NoticeInformation only. Not medical advice. Nothing here is a recommendation to use any substance. Read full disclaimer
22 items
BoxLife Magazine
BoxLife Magazine reports that Luke Hemsworth, 45, discussed using BPC-157 and TB-500 as a “Wolverine stack” for recovery while preparing for The Terminal List Season 2. The excerpt describes purported tissue-repair benefits but provides no clinical evidence supporting those claims.
The Indian Express
The Indian Express reports that US Health Secretary Robert F. Kennedy Jr. announced a draft policy easing compounding access to six experimental peptides under specified conditions. None has FDA approval, and an Indian endocrinologist warns that US enforcement discretion should not be mistaken for medical validation or regulatory approval in India.
HMP Global Learning Network
Tracey C. Vlahovic reviewed evidence linking GLP-1 receptor agonists to lower-extremity outcomes. A cited observational study with 180,740 patients per group reported lower major-amputation risk versus SGLT2 inhibitors, but the review emphasizes that such associations do not establish prevention and that wound-healing and neuropathy benefits remain investigational.
PubMed: BPC-157
Researchers reported stable production of BPC-157 fusion proteins in Bacillus licheniformis, with optimized fermentation increasing reporter-based expression signals approximately threefold. In rats with ethanol-induced acute gastric ulcers, the proteins showed reported ulcer inhibition rates of 75.3%–84.6% across protective and therapeutic experiments.
PubMed: GHK-Cu
Researchers fabricated polypeptide microspheres with attached GHK-Cu and reported enhanced bone-forming and blood-vessel-forming activity in laboratory assays. Compared with microspheres without GHK-Cu, the modified structures increased expression of three bone-formation-related genes by 1.61- to 3.53-fold.
The Times
The Times reports that injecting experimental peptides at social gatherings is becoming more common in wellness circles, including in San Francisco. The article describes interest in recovery, appearance and energy benefits while highlighting medical warnings and limited human evidence.
Business Insider
Business Insider reports that HHS announced conditional enforcement discretion for pharmacies compounding BPC-157 and five other peptides. Human evidence remains scant; a randomized, placebo-controlled trial scheduled for summer 2027 will assess healing and safety in 20 shoulder-surgery patients.
شبكة تواصل الإخبارية
The article reports that actor and martial artist Richard Norton, 75, died on March 30, 2025, after collapsing following a CJC1295 & Ipamorelin injection. It attributes to Victorian coroner David Ryan the finding that the injection triggered his death and that Norton had exceeded the prescribed amount.
Vademecum
A scoping review summarized by Vademecum examined six compounds marketed for musculoskeletal recovery and performance, finding that 67% of identified publications used animal models. Researchers reported that claimed benefits remain unsubstantiated by current human trials, with limited study quality and documented cardiovascular and metabolic risks.
American Lung Association
An American Lung Association article distinguishes approved peptide medicines from unapproved products promoted for lung repair and wellness. Pulmonologist Dr. Mouhib Naddour says promising lung-repair findings mainly come from laboratory and animal studies, with insufficient human evidence that these products improve lung function.
Wonkette
Wonkette reports that HHS Secretary Robert F. Kennedy Jr. announced an enforcement-discretion policy allowing limited compounding of certain peptides under safeguards. The commentary criticizes the policy’s safety implications and cites a reported 33-fold increase in BPC-157 use over six years.
SCNow
A new analysis found that BPC-157, an experimental peptide backed by U.S. Health Secretary Robert F. Kennedy Jr., is being used for varied ailments despite limited human safety and efficacy evidence. SCNow also reports that FDA advisers voted in July to allow pharmacy compounding of the peptide, which remains unapproved for U.S. use.
BGNES
BGNES reports growing interest in peptide injections for anti-aging, while scientists warn that evidence for many experimental products and combinations remains limited. A 2026 review cited in the article found only three human studies of BPC-157, totaling 30 participants, and rated evidence of its benefits as very low quality.
Wave of Long Island
A Wave of Long Island lifestyle article by John Sanchez briefly discusses GHK-Cu and BPC-157 within broader coverage of healthy living in Rockaway. The article describes their research interests in skin processes and tissue repair, while noting that evidence for clinical benefits in humans remains limited, particularly for BPC-157.
inkl
International Business Times reports that HHS announced a temporary policy allowing prescription compounding of six wellness peptides for individual patients under specified conditions. The policy does not grant FDA approval, and the article says their advertised benefits remain scientifically unproven.
Bergen Record
BioRestore Health issued a paid press release comparing stem cells and peptides, emphasizing differences in evidence and regulation. It cited a BPC-157 review containing 36 studies—35 preclinical and one clinical—and stated that evidence is insufficient to establish that experimental stem cell therapies or unapproved peptides reverse human aging or extend lifespan.
7NEWS
7NEWS reports that a coroner linked Australian actor Richard Norton’s death at age 75 to complications from unapproved peptide products. The coroner recommended a safety review and possible further restrictions, while NSW Health reported 1,180 emergency department presentations associated with peptide use between July 2025 and September 2026.
Breitbart News
The article reports that HHS Secretary Robert F. Kennedy Jr. announced a policy allowing access to unapproved peptide injections through FDA enforcement discretion. HHS says the policy protects patient choice and safety, while the report describes bypassed approval safeguards and concerns from former and current FDA officials.
Yahoo News Singapore
A Reader’s Digest article carried by Yahoo News Singapore examines growing interest in wellness peptides, contrasting personal testimonials with limited human evidence and safety concerns. It also reports that Health and Human Services Secretary Robert F. Kennedy Jr. announced plans to ease restrictions on 14 peptides.
Newsmax
Newsmax reports that HHS plans to exercise enforcement discretion to allow compounding pharmacies to produce six experimental peptides while pursuing a permanent rule change. None is FDA-approved, and agency scientists say evidence is insufficient to establish their safety or effectiveness.